Stockscreener 앱 받기
25.52
0.31%
-0.005
Apellis Pharmaceuticals Inc 주식(APLS)의 최신 뉴스
Will Apellis Pharma's Empaveli Prove VALIANT In Battling Rare Kidney Diseases? - RTTNews
Learn to Evaluate (APLS) using the Charts - Stock Traders Daily
Apellis Pharmaceuticals general counsel sells shares for $139,789 By Investing.com - Investing.com South Africa
Insider Sells Thousands of Apellis Pharmaceuticals Shares! - TipRanks
Apellis Pharmaceuticals general counsel sells shares for $139,789 - Investing.com India
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics - MSN
HC Wainwright Issues Pessimistic Forecast for APLS Earnings - Defense World
Wedbush Lifts Earnings Estimates for Apellis Pharmaceuticals - Defense World
Wedbush Issues Optimistic Outlook for APLS Earnings - Defense World
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues - MSN
Apellis Pharmaceuticals: A Mixed Bag (NASDAQ:APLS) - Seeking Alpha
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Benzinga
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript - MSN
JPMorgan Chase & Co. Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $29.00 by Analysts at Wedbush - Defense World
Apellis Pharmaceuticals’ (APLS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $32.00 at The Goldman Sachs Group - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $25.00 at Royal Bank of Canada - Defense World
Apellis Class Action: Levi & Korsinsky Reminds Apellis Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 2, 2023 – APLS - ACCESS Newswire
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views - Benzinga
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Apellis Pharmaceuticals, Inc.(APLS) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
New York State Common Retirement Fund Sells 327,776 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Apellis Pharmaceuticals, Inc. (APLS) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week Low – What’s Next? - Defense World
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus.com
Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Apellis Pharmaceuticals CFO sells shares worth $93,953 - MSN
Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
Apellis Pharmaceuticals' chief business officer sells $10,359 in stock - MSN
Apellis Pharmaceuticals Reports Strong 2024 Growth - TipRanks
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Apellis Pharmaceuticals: Strong Buy Rating Maintained Amid Market Share Adjustments - TipRanks
Apellis Pharma stock hits 52-week low at $24.34 amid market challenges - Investing.com Australia
Apellis Pharmaceuticals reports Q4 revenue beat, shares fall on Syfovre guidance - Investing.com Australia
Apellis Pharma stock hits 52-week low at $24.34 amid market challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Apellis Pharmaceuticals Q4 2024 sees revenue surge - Investing.com
Earnings call transcript: Apellis Pharmaceuticals Q4 2024 sees revenue surge By Investing.com - Investing.com South Africa
Apellis Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Why Apellis Pharmaceuticals Shares Are in Flux - TipRanks
Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 Net Loss $-0.29 a Share, vs. FactSet Est of $-0.37 Loss - Marketscreener.com
APELLIS PHARMACEUTICALS Earnings Results: $APLS Reports Quarterly Earnings - Nasdaq
Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 Revenue $212.5M, vs. FactSet Est of $198.8M - Marketscreener.com
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Apellis Pharmaceuticals Q4 Net Loss Narrows, Revenue Rises -February 28, 2025 at 07:28 am EST - Marketscreener.com
0.17%
8.65%
자본화:
|
볼륨(24시간):